Background
AbbVie is developing ABBV-101, a Bruton’s tyrosine kinase (BTK) degrader — a class of cancer therapy compounds designed to selectively destroy the BTK protein implicated in blood and bone marrow cancers. BTK degrader molecules consist of three structural components: a target binding ligand (TBL), an E3-ligase binding ligand (LBL), and a linker connecting them. AbbVie alleges it developed proprietary designs for each of these components through years of research.
Huaqing Liu worked at Abbott/AbbVie for over 22 years, including as a Senior Research Scientist on the BTK degrader program from September 2018. In September 2019, Liu announced his “retirement,” relocated to Beijing, and immediately began work as Executive Director of Chemistry at BeiGene. Within six months of Liu’s arrival, BeiGene filed its first post-Liu patent application — one of six that AbbVie alleges incorporated AbbVie’s proprietary compound designs. BeiGene’s drug candidate BGB-16673, which holds FDA fast-track designation and is in global clinical trials, allegedly builds on those designs.
AbbVie sued under the Defend Trade Secrets Act (DTSA), alleging that BeiGene deliberately recruited Liu to obtain AbbVie’s BTK degrader trade secrets. BeiGene moved to dismiss, arguing AbbVie failed to adequately plead the existence of trade secrets, misappropriation, and specificity.
The Court’s Holding
Judge Cummings denied the motion to dismiss in its entirety, finding AbbVie’s complaint plausibly stated a DTSA claim at each contested element.
On trade secret existence, the court rejected BeiGene’s argument that some of AbbVie’s claimed structures appeared in BeiGene’s pre-Liu patent filing. The court found BeiGene’s characterization inaccurate — BeiGene’s pre-Liu linker definitions encompassed longer structures with additional functional groups, distinct from AbbVie’s short cyclic amine designs. Even where individual sub-structures might appear publicly, “trade secret combinations of those structures with certain other sub-structures do not.” The court also held that AbbVie’s security measures — access limited to approved employees, secure network storage, NDAs, and Code of Conduct training — were sufficient, rejecting BeiGene’s demand for “differentiated heightened protection” specifically for the BTK degrader program.
On misappropriation, the court emphasized that “trade secrets can exist in employees’ memories” and that no tangible document theft is required. AbbVie’s allegations of Liu’s deep access, the suspicious circumstances of his departure, and the “impossibly fast timeframe” in which BeiGene filed patent applications incorporating AbbVie’s designs were sufficient to create a plausible inference of misappropriation.
Key Takeaways
- Trade secrets live in memory, not just documents. The court reaffirmed that DTSA claims don’t require evidence that an employee physically took files or documents. Knowledge carried in an employee’s memory can constitute trade secret misappropriation.
- Rapid post-hire patent filings create strong circumstantial evidence. BeiGene filing patent applications incorporating AbbVie’s alleged designs within six months of Liu’s arrival established a plausible “sharp change in direction” supporting misappropriation.
- Combinations are protectable even when components are public. Individual chemical sub-structures appearing in prior art do not defeat trade secret claims when the specific combinations and design methodologies remain confidential.
- No heightened pleading for DTSA claims. The court rejected any requirement for heightened specificity, holding that trade secrets can be pled “in broad strokes” at the motion-to-dismiss stage.
Why It Matters
This case sits at the intersection of two high-stakes trends: the pharmaceutical industry’s increasing reliance on trade secret protection for drug development data, and the global competition for scientific talent between U.S. and Chinese companies. BeiGene’s BGB-16673 is a potentially blockbuster cancer drug with FDA fast-track status, and the outcome of this litigation could affect its commercial trajectory. For the broader pharma and biotech industry, the ruling that employee memory-based trade secret claims can survive dismissal — even without evidence of document theft — lowers the bar for companies seeking to protect proprietary compound designs against departing scientists. Companies hiring senior researchers from competitors should expect heightened scrutiny when their post-hire innovations closely track the hire’s former employer’s proprietary research.